Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

globenewswire

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma – NEWSnet – News… as it used to be

More Press Releases

May 9, 2026

ADSQUIRE Creates Another Legal Marketing First By Being The First Ad Agency To Place A Lawyer Advertisement On ChatGPT

May 9, 2026

Crypto News: Pepeto Announces Exchange Progress While Bitcoin Price Prediction From Arthur Hayes Targets $125,000 by December

May 9, 2026

A Pint for Kim Blood Drive Breaks Illinois Record for the Seventh Year in a Row with over 650 Donations in One Day

May 9, 2026

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

ADSQUIRE Creates Another Legal Marketing First By Being The First Ad Agency To Place A Lawyer Advertisement On ChatGPT

Crypto News: Pepeto Announces Exchange Progress While Bitcoin Price Prediction From Arthur Hayes Targets $125,000 by December

A Pint for Kim Blood Drive Breaks Illinois Record for the Seventh Year in a Row with over 650 Donations in One Day

Crypto News: AlphaPepe Announces Stage 16 Presale Live Whilst Ethereum Price Prediction Points To $8,000